

# Victoria P Werth

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8631746/victoria-p-werth-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

304  
papers

12,888  
citations

53  
h-index

106  
g-index

383  
ext. papers

16,231  
ext. citations

4  
avg, IF

6.52  
L-index

#	Paper	IF	Citations
304	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 2677-86		2688
303	Anifrolumab, an Anti-Interferon- $\gamma$ Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 376-386	9.5	430
302	2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1955-1964	2.4	393
301	Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. <i>Journal of the American Academy of Dermatology</i> , <b>2008</b> , 58, 1043-6	4.5	372
300	Sifalimumab, an anti-interferon- $\gamma$ monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 1909-1916	2.4	309
299	The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. <i>Journal of Investigative Dermatology</i> , <b>2005</b> , 125, 889-94	4.3	280
298	Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. <i>Journal of the American Academy of Dermatology</i> , <b>2011</b> , 64, 217-28; quiz 229-30	4.5	249
297	European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 1269-74	2.4	245
296	2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 2271-2282	9.5	210
295	Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity	4.7	203
294	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 554-561 suppl 11, S118-37	2.4	175
293	Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. <i>Lancet, The</i> , <b>2018</b> , 392, 1330-1339	4.0	161
292	Cutaneous lupus erythematosus: diagnosis and treatment. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2013</b> , 27, 391-404	5.3	152
291	Reliability and convergent validity of two outcome instruments for pemphigus. <i>Journal of Investigative Dermatology</i> , <b>2009</b> , 129, 2404-10	4.3	149
290	International consensus for a definition of disease flare in lupus. <i>Lupus</i> , <b>2011</b> , 20, 453-62	2.6	127
289	Diagnosis and management of pemphigus: Recommendations of an international panel of experts. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 82, 575-585.e1	4.5	127
288	Update on morphea: part II. Outcome measures and treatment. <i>Journal of the American Academy of Dermatology</i> , <b>2011</b> , 64, 231-42; quiz 243-4	4.5	122

287	Classification of myositis. <i>Nature Reviews Rheumatology</i> , <b>2018</b> , 14, 269-278	8.1	117
286	Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. <i>Journal of Clinical Investigation</i> , <b>2019</b> , 129, 1359-1371	15.9	110
285	Mycophenolate mofetil for interstitial lung disease in dermatomyositis. <i>Arthritis Care and Research</i> , <b>2010</b> , 62, 1496-501	4.7	106
284	Cutaneous lupus erythematosus: a review. <i>Dermatologic Clinics</i> , <b>2002</b> , 20, 373-85, v	4.2	105
283	TNF-alpha production in the skin. <i>Archives of Dermatological Research</i> , <b>2009</b> , 301, 87-91	3.3	104
282	Quality of life in cutaneous lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , <b>2011</b> , 64, 849-58	4.5	103
281	Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. <i>Archives of Dermatology</i> , <b>2011</b> , 147, 203-8		101
280	Association of a promoter polymorphism of tumor necrosis factor-alpha with subacute cutaneous lupus erythematosus and distinct photoregulation of transcription. <i>Journal of Investigative Dermatology</i> , <b>2000</b> , 115, 726-30	4.3	101
279	A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. <i>Journal of the American Academy of Dermatology</i> , <b>2011</b> , 64, 903-8	4.5	100
278	Clinical manifestations of cutaneous lupus erythematosus. <i>Autoimmunity Reviews</i> , <b>2005</b> , 4, 296-302	13.6	95
277	Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. <i>Archives of Dermatology</i> , <b>2011</b> , 147, 1261-7		94
276	Definitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of experts. <i>Journal of the American Academy of Dermatology</i> , <b>2015</b> , 72, 168-74	4.5	93
275	The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score. <i>British Journal of Dermatology</i> , <b>2012</b> , 166, 971-5	4	89
274	Deletion of decay-accelerating factor (CD55) exacerbates autoimmune disease development in MRL/lpr mice. <i>American Journal of Pathology</i> , <b>2002</b> , 161, 1077-86	5.8	88
273	Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. <i>Archives of Dermatology</i> , <b>2012</b> , 148, 1031-6		86
272	UVB and proinflammatory cytokines synergistically activate TNF-alpha production in keratinocytes through enhanced gene transcription. <i>Journal of Investigative Dermatology</i> , <b>2009</b> , 129, 994-1001	4.3	85
271	Prevention and management of glucocorticoid-induced side effects: A comprehensive review: A review of glucocorticoid pharmacology and bone health. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 76, 1-9	4.5	81
270	Dermatology position paper on the revision of the 1982 ACR criteria for systemic lupus erythematosus. <i>Lupus</i> , <b>2004</b> , 13, 839-49	2.6	78

269	Impact of smoking in cutaneous lupus erythematosus. <i>Archives of Dermatology</i> , <b>2012</b> , 148, 317-22		75
268	The cutaneous lupus erythematosus disease area and severity index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus. <i>Archives of Dermatology</i> , <b>2008</b> , 144, 173-80		75
267	Pathophysiology of cutaneous lupus erythematosus. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2007</b> , 33, 85-106	12.3	75
266	Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. <i>British Journal of Dermatology</i> , <b>2008</b> , 159, 887-94	4	70
265	Interventions for pemphigus vulgaris and pemphigus foliaceus. <i>The Cochrane Library</i> , <b>2009</b> , CD006263	5.2	68
264	Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial. <i>JAMA Dermatology</i> , <b>2015</b> , 151, 952-60	5.1	66
263	EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. <i>RMD Open</i> , <b>2017</b> , 3, e000507	5.9	66
262	Pathophysiology of cutaneous lupus erythematosus. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 182	5.7	65
261	Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. <i>Archives of Dermatology</i> , <b>2008</b> , 144, 25-32		64
260	Associations of tumor necrosis factor alpha and HLA polymorphisms with adult dermatomyositis: implications for a unique pathogenesis. <i>Journal of Investigative Dermatology</i> , <b>2002</b> , 119, 617-20	4.3	64
259	Cutaneous Lupus Erythematosus: An Update on Pathogenesis, Diagnosis and Treatment. <i>American Journal of Clinical Dermatology</i> , <b>2016</b> , 17, 135-46	7.1	62
258	Quality of life in dermatomyositis. <i>Journal of the American Academy of Dermatology</i> , <b>2011</b> , 65, 1107-16	4.5	62
257	Systemic symptoms in the progression of cutaneous to systemic lupus erythematosus. <i>JAMA Dermatology</i> , <b>2014</b> , 150, 291-6	5.1	61
256	Tumid lupus erythematosus: criteria for classification with immunohistochemical analysis. <i>Arthritis and Rheumatism</i> , <b>2003</b> , 49, 494-500		61
255	Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study. <i>Archives of Dermatology</i> , <b>2005</b> , 141, 855-9		61
254	Incidence of alopecia areata in lupus erythematosus. <i>Archives of Dermatology</i> , <b>1992</b> , 128, 368-371		59
253	Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. <i>Autoimmunity Reviews</i> , <b>2011</b> , 10, 383-8	13.6	55
252	239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018. <i>Neuromuscular Disorders</i> , <b>2020</b> , 30, 70-92	2.9	53

251	Calculation of cut-off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus. <i>British Journal of Dermatology</i> , <b>2016</b> , 175, 142-9	4	52
250	Resistant discoid lupus erythematosus of palms and soles: successful treatment with azathioprine. <i>Journal of the American Academy of Dermatology</i> , <b>1988</b> , 19, 961-5	4.5	51
249	Brief Report: Pharmacodynamics, Safety, and Clinical Efficacy of AMG 811, a Human Anti-Interferon- $\gamma$ Antibody, in Patients With Discoid Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 1028-1034	9.5	50
248	The role of cytokines in the pathogenesis of cutaneous lupus erythematosus. <i>Cytokine</i> , <b>2015</b> , 73, 326-344	4	50
247	Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change. <i>British Journal of Dermatology</i> , <b>2015</b> , 173, 969-74	4	47
246	The Cutaneous Lupus Erythematosus Disease Activity and Severity Index: expansion for rheumatology and dermatology. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 59, 338-44		47
245	Small vessel vasculitis of the skin. <i>Rheumatic Disease Clinics of North America</i> , <b>2015</b> , 41, 21-32, vii	2.4	46
244	Treatment of cutaneous lupus. <i>Current Rheumatology Reports</i> , <b>2011</b> , 13, 300-7	4.9	46
243	Prevention and management of glucocorticoid-induced side effects: A comprehensive review: Gastrointestinal and endocrinologic side effects. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 76, 11-16	4.5	45
242	Multicentric reticulohistiocytosis presenting with clinical features of dermatomyositis. <i>Journal of the American Academy of Dermatology</i> , <b>2003</b> , 48, S11-4	4.5	45
241	Development of the CLASI as an outcome instrument for cutaneous lupus erythematosus. <i>Dermatologic Therapy</i> , <b>2007</b> , 20, 93-101	2.2	44
240	Prevention and management of glucocorticoid-induced side effects: A comprehensive review: Ocular, cardiovascular, muscular, and psychiatric side effects and issues unique to pediatric patients. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 76, 201-207	4.5	43
239	Lupus community panel proposals for optimising clinical trials: 2018. <i>Lupus Science and Medicine</i> , <b>2018</b> , 5, e000258	4.6	43
238	Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare. <i>Journal of the American Academy of Dermatology</i> , <b>2012</b> , 66, 571-82	4.5	43
237	Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument. <i>British Journal of Dermatology</i> , <b>2010</b> , 162, 669-73	4	43
236	Mannose binding lectin (MBL) polymorphisms associated with low MBL production in patients with dermatomyositis. <i>Journal of Investigative Dermatology</i> , <b>2002</b> , 119, 1394-9	4.3	43
235	Interstitial lung disease in classic and skin-predominant dermatomyositis: a retrospective study with screening recommendations. <i>Archives of Dermatology</i> , <b>2010</b> , 146, 729-38		41
234	A multicentre, cross-sectional study on quality of life in patients with cutaneous lupus erythematosus. <i>British Journal of Dermatology</i> , <b>2013</b> , 168, 145-53	4	40

233	Prevention and management of glucocorticoid-induced side effects: A comprehensive review: Infectious complications and vaccination recommendations. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 76, 191-198	4.5	39
232	Pemphigus. <i>Dental Clinics of North America</i> , <b>2013</b> , 57, 597-610	3.3	39
231	Number, characteristics, and classification of patients with dermatomyositis seen by dermatology and rheumatology departments at a large tertiary medical center. <i>Journal of the American Academy of Dermatology</i> , <b>2007</b> , 57, 937-43	4.5	39
230	Lenalidomide for the treatment of resistant discoid lupus erythematosus. <i>Archives of Dermatology</i> , <b>2009</b> , 145, 303-6		38
229	Cross-sectional analysis of a collaborative Web-based database for lupus erythematosus-associated skin lesions: prospective enrollment of 114 patients. <i>Archives of Dermatology</i> , <b>2009</b> , 145, 255-60		38
228	Prevalence of self-report photosensitivity in cutaneous lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , <b>2012</b> , 66, 220-8	4.5	37
227	Translocation of Endogenous Danger Signal HMGB1 From Nucleus to Membrane Microvesicles in Macrophages. <i>Journal of Cellular Physiology</i> , <b>2016</b> , 231, 2319-26	7	37
226	A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone. <i>British Journal of Dermatology</i> , <b>2015</b> , 172, 760-8	4	36
225	Itch in dermatomyositis: the role of increased skin interleukin-31. <i>British Journal of Dermatology</i> , <b>2018</b> , 179, 669-678	4	36
224	Management of cutaneous dermatomyositis: current therapeutic options. <i>American Journal of Clinical Dermatology</i> , <b>2006</b> , 7, 341-51	7.1	36
223	Cutaneous lupus: insights into pathogenesis and disease classification. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , <b>2007</b> , 65, 200-4		36
222	Development of classification criteria for discoid lupus erythematosus: Results of a Delphi exercise. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 77, 261-267	4.5	34
221	The impact of skin damage due to cutaneous lupus on quality of life. <i>British Journal of Dermatology</i> , <b>2014</b> , 170, 315-21	4	34
220	Stroke and deep venous thrombosis complicating intravenous immunoglobulin infusions. <i>Archives of Dermatology</i> , <b>2003</b> , 139, 991-3		34
219	Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial. <i>Journal of the American Academy of Dermatology</i> , <b>2014</b> , 70, 583-4	4.5	33
218	Large International Validation of ABSIS and PDAI Pemphigus Severity Scores. <i>Journal of Investigative Dermatology</i> , <b>2019</b> , 139, 31-37	4.3	33
217	Microvesicles in Autoimmune Diseases. <i>Advances in Clinical Chemistry</i> , <b>2016</b> , 77, 125-175	5.8	32
216	Characterization of clinical photosensitivity in cutaneous lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , <b>2013</b> , 69, 205-13	4.5	32

215	Grading criteria for disease severity by pemphigus disease area index. <i>Journal of Dermatology</i> , <b>2014</b> , 41, 969-73	1.6	32
214	Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM. <i>Journal of Investigative Dermatology</i> , <b>2012</b> , 132, 1117-24	4.3	32
213	Treatment of dermatologic connective tissue disease and autoimmune blistering disorders in pregnancy. <i>Dermatologic Therapy</i> , <b>2013</b> , 26, 354-63	2.2	31
212	Analysis of compact fluorescent lights for use by patients with photosensitive conditions. <i>Photochemistry and Photobiology</i> , <b>2009</b> , 85, 1004-10	3.6	31
211	Dermatomyositis. <i>Current Directions in Autoimmunity</i> , <b>2008</b> , 10, 313-32		31
210	Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , <b>2018</b> , 5, e000284	4.6	31
209	Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 78, 100-106.e1	4.5	30
208	The importance of including amyopathic dermatomyositis in the idiopathic inflammatory myositis spectrum. <i>Clinical and Experimental Rheumatology</i> , <b>2013</b> , 31, 128-34	2.2	30
207	Rituximab in the treatment of bullous systemic lupus erythematosus. <i>Journal of Clinical Rheumatology</i> , <b>2011</b> , 17, 142-4	1.1	29
206	Elastic fiber-associated proteins of skin in development and photoaging. <i>Photochemistry and Photobiology</i> , <b>1996</b> , 63, 308-13	3.6	29
205	Tumor necrosis factor $\alpha$ release in peripheral blood mononuclear cells of cutaneous lupus and dermatomyositis patients. <i>Arthritis Research and Therapy</i> , <b>2012</b> , 14, R1	5.7	28
204	The risk of ultraviolet radiation exposure from indoor lamps in lupus erythematosus. <i>Autoimmunity Reviews</i> , <b>2009</b> , 8, 320-4	13.6	28
203	Dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. <i>Archives of Dermatology</i> , <b>2005</b> , 141, 699-702		28
202	Quality of life in patients with bullous dermatoses. <i>Clinics in Dermatology</i> , <b>2012</b> , 30, 103-7	3	27
201	Lupus erythematosus induced by medications, ultraviolet radiation, and other exogenous agents: a review, with special focus on the development of subacute cutaneous lupus erythematosus in a genetically predisposed individual. <i>International Journal of Dermatology</i> , <b>2004</b> , 43, 87-94	1.7	27
200	Applicability of EULAR/ACR classification criteria for dermatomyositis to amyopathic disease. <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 79, 77-83.e1	4.5	26
199	Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus. <i>JAMA Dermatology</i> , <b>2019</b> , 155, 1404-1409	5.1	26
198	Animal models of acute photodamage: comparisons of anatomic, cellular and molecular responses in C57BL/6J, SKH1 and Balb/c mice. <i>Photochemistry and Photobiology</i> , <b>2011</b> , 87, 690-8	3.6	26

197	UVB irradiation alters cellular responses to cytokines: role in extracellular matrix gene expression. <i>Journal of Investigative Dermatology</i> , <b>1997</b> , 108, 290-4	4.3	26
196	Ultraviolet irradiation induces the accumulation of chondroitin sulfate, but not other glycosaminoglycans, in human skin. <i>PLoS ONE</i> , <b>2011</b> , 6, e14830	3.7	26
195	Reliability and convergent validity of the cutaneous sarcoidosis activity and morphology instrument for assessing cutaneous sarcoidosis. <i>JAMA Dermatology</i> , <b>2013</b> , 149, 550-6	5.1	25
194	Photosensitivity in rheumatic diseases. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , <b>2004</b> , 9, 57-63	1.1	25
193	The early local and systemic Type I interferon responses to ultraviolet B light exposure are cGAS dependent. <i>Scientific Reports</i> , <b>2020</b> , 10, 7908	4.9	24
192	Update on management of connective tissue panniculitides. <i>Dermatologic Therapy</i> , <b>2012</b> , 25, 173-82	2.2	24
191	Biological therapies in the treatment of cutaneous lupus erythematosus. <i>Lupus</i> , <b>2017</b> , 26, 115-118	2.6	24
190	IL-12 completely blocks ultraviolet-induced secretion of tumor necrosis factor alpha from cultured skin fibroblasts and keratinocytes. <i>Journal of Investigative Dermatology</i> , <b>2003</b> , 120, 116-22	4.3	24
189	A cross-sectional study of untreated depression and anxiety in cutaneous lupus erythematosus and dermatomyositis. <i>Journal of the American Academy of Dermatology</i> , <b>2016</b> , 74, 377-9	4.5	23
188	Using the American College of Rheumatology (ACR) and Systemic Lupus International Collaborating Clinics (SLICC) criteria to determine the diagnosis of systemic lupus erythematosus (SLE) in patients with subacute cutaneous lupus erythematosus (SCLE). <i>Journal of the American Academy of Dermatology</i> , <b>2016</b> , 74, 862-9	4.5	23
187	The systemic management of cutaneous dermatomyositis: Results of a stepwise strategy. <i>International Journal of Women's Dermatology</i> , <b>2017</b> , 3, 189-194	2	23
186	Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life. <i>British Journal of Dermatology</i> , <b>2015</b> , 172, 169-74	4	23
185	Quality of life differences between responders and nonresponders in the treatment of cutaneous lupus erythematosus. <i>JAMA Dermatology</i> , <b>2013</b> , 149, 104-6	5.1	23
184	Cigarette smoking and response to antimalarials in cutaneous lupus erythematosus patients: evolution of a dogma. <i>Journal of Investigative Dermatology</i> , <b>2011</b> , 131, 1968-70	4.3	23
183	Alopecias in lupus erythematosus. <i>Lupus Science and Medicine</i> , <b>2018</b> , 5, e000291	4.6	23
182	Cannabinoid Reduces Inflammatory Cytokines, Tumor Necrosis Factor- $\alpha$ and Type I Interferons in Dermatomyositis In Vitro. <i>Journal of Investigative Dermatology</i> , <b>2017</b> , 137, 2445-2447	4.3	22
181	Cutaneous lupus and the Cutaneous Lupus Erythematosus Disease Area and Severity Index instrument. <i>Rheumatic Disease Clinics of North America</i> , <b>2010</b> , 36, 33-51, vii	2.4	22
180	Thalidomide in cutaneous lupus erythematosus. <i>American Journal of Clinical Dermatology</i> , <b>2003</b> , 4, 379-87.1		22

179	Quinacrine Suppresses Tumor Necrosis Factor- $\alpha$ and IFN- $\gamma$ in Dermatomyositis and Cutaneous Lupus Erythematosus. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , <b>2017</b> , 18, S57-S63	1.1	21
178	Wavelength-specific synergy between ultraviolet radiation and interleukin-1 alpha in the regulation of matrix-related genes: mechanistic role for tumor necrosis factor-alpha. <i>Journal of Investigative Dermatology</i> , <b>1999</b> , 113, 196-201	4.3	21
177	The diagnosis and classification of amyopathic dermatomyositis: a historical review and assessment of existing criteria. <i>British Journal of Dermatology</i> , <b>2019</b> , 180, 1001-1008	4	21
176	Reliability of the autoimmune bullous disease quality of life (ABQOL) questionnaire in the USA. <i>Quality of Life Research</i> , <b>2015</b> , 24, 2257-60	3.7	20
175	Therapeutic Elimination of the Type 1 Interferon Receptor for Treating Psoriatic Skin Inflammation. <i>Journal of Investigative Dermatology</i> , <b>2016</b> , 136, 1990-2002	4.3	20
174	Identification and molecular analysis of glycosaminoglycans in cutaneous lupus erythematosus and dermatomyositis. <i>Journal of Histochemistry and Cytochemistry</i> , <b>2011</b> , 59, 336-45	3.4	20
173	Increased Myeloid Dendritic Cells and TNF- $\alpha$ Expression Predicts Poor Response to Hydroxychloroquine in Cutaneous Lupus Erythematosus. <i>Journal of Investigative Dermatology</i> , <b>2019</b> , 139, 324-332	4.3	20
172	Effect of Hydroxychloroquine and Anti-BDCA2 mAb Treatment on pDC IFN- $\alpha$ Production From Patients Affected With Cutaneous Lupus Erythematosus. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 275	8.4	19
171	Dapsone in the management of autoimmune bullous diseases. <i>Dermatologic Clinics</i> , <b>2011</b> , 29, 561-4	4.2	19
170	Squamous cell carcinomas arising in discoid lupus erythematosus scars: unusual occurrence in an African-American and in a sun-protected area. <i>Journal of Clinical Rheumatology</i> , <b>2011</b> , 17, 35-6	1.1	18
169	Pathogenetic mechanisms and treatment of cutaneous lupus erythematosus. <i>Current Opinion in Rheumatology</i> , <b>1997</b> , 9, 400-9	5.3	18
168	Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool-Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists. <i>British Journal of Dermatology</i> , <b>2017</b> , 177, 1086-1092	4	17
167	Redefining cutaneous lupus erythematosus: a proposed international consensus approach and results of a preliminary questionnaire. <i>Lupus Science and Medicine</i> , <b>2015</b> , 2, e000085	4.6	17
166	Systemic sclerosis: Current concepts of skin and systemic manifestations. <i>Clinics in Dermatology</i> , <b>2018</b> , 36, 459-474	3	17
165	Management of rheumatic and autoimmune blistering disease in pregnancy and postpartum. <i>Clinics in Dermatology</i> , <b>2016</b> , 34, 344-52	3	17
164	Clinical outcome measures for cutaneous lupus erythematosus. <i>Lupus</i> , <b>2010</b> , 19, 1137-43	2.6	17
163	Development of outcome measures for autoimmune dermatoses. <i>Archives of Dermatological Research</i> , <b>2008</b> , 300, 3-9	3.3	17
162	Nuclear envelope rupture and NET formation is driven by PKC-mediated lamin B disassembly. <i>EMBO Reports</i> , <b>2020</b> , 21, e48779	6.5	17

161	Dermatomyositis: A diagnostic dilemma. <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 79, 371-373	4.3	16
160	Re-examining mechanic hands as a characteristic skin finding in dermatomyositis. <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 78, 769-775.e2	4.5	16
159	Gottron papules exhibit dermal accumulation of CD44 variant 7 (CD44v7) and its binding partner osteopontin: a unique molecular signature. <i>Journal of Investigative Dermatology</i> , <b>2012</b> , 132, 1825-32	4.3	16
158	Developing classification criteria for skin-predominant dermatomyositis: the Delphi process. <i>British Journal of Dermatology</i> , <b>2020</b> , 182, 410-417	4	16
157	Treatment of Autoimmune Bullous Disorders in Pregnancy. <i>American Journal of Clinical Dermatology</i> , <b>2018</b> , 19, 391-403	7.1	15
156	Update on pathogenesis and treatment of CLE. <i>Current Opinion in Rheumatology</i> , <b>2013</b> , 25, 584-90	5.3	15
155	Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific Conference. <i>Frontiers in Medicine</i> , <b>2018</b> , 5, 306	4.9	15
154	Reliability and Validity of Cutaneous Sarcoidosis Outcome Instruments Among Dermatologists, Pulmonologists, and Rheumatologists. <i>JAMA Dermatology</i> , <b>2015</b> , 151, 1317-1322	5.1	14
153	Decreased secretion of adiponectin through its intracellular accumulation in adipose tissue during tobacco smoke exposure. <i>Nutrition and Metabolism</i> , <b>2015</b> , 12, 15	4.6	14
152	Quality of life and disease severity in a cutaneous lupus erythematosus pilot study. <i>Archives of Dermatology</i> , <b>2008</b> , 144, 1061-2		14
151	Dermatologic therapeutics: thalidomide. A practical guide. <i>Dermatologic Therapy</i> , <b>2007</b> , 20, 175-86	2.2	14
150	Ultraviolet-B recruits mannose-binding lectin into skin from non-cutaneous sources. <i>Journal of Investigative Dermatology</i> , <b>2005</b> , 125, 166-73	4.3	14
149	Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 2295-2305	59.2	14
148	Clinical signs associated with an increased risk of interstitial lung disease: a retrospective study of 101 patients with dermatomyositis. <i>British Journal of Dermatology</i> , <b>2017</b> , 176, 231-233	4	13
147	Dapsone in the management of autoimmune bullous diseases. <i>Immunology and Allergy Clinics of North America</i> , <b>2012</b> , 32, 317-22, vii	3.3	13
146	Incidence of alopecia areata in lupus erythematosus. <i>Archives of Dermatology</i> , <b>1992</b> , 128, 368-71		13
145	Cutaneous lupus erythematosus induced by drugs - novel insights. <i>Expert Review of Clinical Pharmacology</i> , <b>2020</b> , 13, 35-42	3.8	13
144	Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study. <i>British Journal of Dermatology</i> , <b>2021</b> , 185, 745-755	4	13

143	The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) among dermatologists, rheumatologists and neurologists. <i>British Journal of Dermatology</i> , <b>2017</b> , 176, 423-430	4	12
142	Treatment of cutaneous lupus erythematosus: current practice variations. <i>Lupus</i> , <b>2016</b> , 25, 964-72	2.6	12
141	Subacute cutaneous lupus erythematosus and systemic lupus erythematosus associated with abatacept. <i>JAAD Case Reports</i> , <b>2018</b> , 4, 698-700	1.4	12
140	A47: Progress Report on the Development of New Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies. <i>Arthritis and Rheumatology</i> , <b>2014</b> , 66, S70-S71	9.5	12
139	Rheumatic manifestations of skin disease. <i>Current Opinion in Rheumatology</i> , <b>2010</b> , 22, 78-84	5.3	12
138	Glucocorticoids in the treatment of bullous diseases. <i>Dermatologic Therapy</i> , <b>2002</b> , 15, 298-310	2.2	12
137	213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18-20 September 2015. <i>Neuromuscular Disorders</i> , <b>2016</b> , 26, 523-34	2.9	12
136	Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosus-An Ongoing Need for International Consensus and Collaborations. <i>Journal of Investigative Dermatology</i> , <b>2019</b> , 139, 270-276	4.3	12
135	A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies. <i>Rheumatology</i> , <b>2021</b> , 60, 2615-2628	3.9	12
134	A review of cutaneous lupus erythematosus: improving outcomes with a multidisciplinary approach. <i>Journal of Multidisciplinary Healthcare</i> , <b>2019</b> , 12, 419-428	2.8	11
133	Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus. <i>Science Translational Medicine</i> , <b>2021</b> , 13,	17.5	11
132	Computerized planimetry to assess clinical responsiveness in a phase II randomized trial of topical R333 for discoid lupus erythematosus. <i>British Journal of Dermatology</i> , <b>2018</b> , 178, 1308-1314	4	10
131	Cutaneous dermatomyositis disease course followed over time using the Cutaneous Dermatomyositis Disease Area and Severity Index. <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 79, 464-469.e2	4.5	10
130	Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects. <i>Expert Review of Clinical Immunology</i> , <b>2016</b> , 12, 1109-21	5.1	10
129	Evaluation of the reliability and validity of the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) in paediatric cutaneous lupus among paediatric dermatologists and rheumatologists. <i>British Journal of Dermatology</i> , <b>2019</b> , 180, 165-171	4	10
128	The quinacrine experience in a population of patients with cutaneous lupus erythematosus and dermatomyositis. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 77, 374-377	4.5	10
127	Preserving medical dermatology. A colleague lost, a call to arms, and a plan for battle. <i>Dermatologic Clinics</i> , <b>2001</b> , 19, 583-92	4.2	10
126	Accidental hydroxychloroquine overdose resulting in neurotoxic vestibulopathy. <i>BMJ Case Reports</i> , <b>2017</b> , 2017,	0.9	10

125	American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 Joint Statement on Hydroxychloroquine Use With Respect to Retinal Toxicity. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 908-911	9.5	10
124	Cutaneous Lupus Erythematosus Patients With a Negative Antinuclear Antibody Meeting the American College of Rheumatology and/or Systemic Lupus International Collaborating Clinics Criteria for Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 1404-1409	4.7	9
123	Lack of correlation of skin thickness with bone density in patients receiving chronic glucocorticoid. <i>Archives of Dermatological Research</i> , <b>1998</b> , 290, 388-93	3.3	9
122	Treatment of Discoid Skin Lesions With Azathioprine. <i>Archives of Dermatology</i> , <b>1986</b> , 122, 746		9
121	Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. <i>Archives of Dermatology</i> , <b>1996</b> , 132, 1435-9		9
120	Malignancy in dermatomyositis: A retrospective study of 201 patients seen at the University of Pennsylvania. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 83, 117-122	4.5	8
119	Advancing understanding, diagnosis, and therapies for cutaneous lupus erythematosus within the broader context of systemic lupus erythematosus. <i>F1000Research</i> , <b>2019</b> , 8,	3.6	8
118	Blood plasma versus serum: which is right for sampling circulating membrane microvesicles in human subjects?. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, e73	2.4	8
117	Practice-based differences in paediatric discoid lupus erythematosus. <i>British Journal of Dermatology</i> , <b>2019</b> , 181, 805-810	4	7
116	Practice and Educational Gaps in Lupus, Dermatomyositis, and Morphea. <i>Dermatologic Clinics</i> , <b>2016</b> , 34, 243-50	4.2	7
115	Prevalence of Pruritus in Cutaneous Lupus Erythematosus: Brief Report of a Multicenter, Multinational Cross-Sectional Study. <i>BioMed Research International</i> , <b>2018</b> , 2018, 3491798	3	7
114	Thalidomide-induced orofacial neuropathy. <i>Journal of Clinical Rheumatology</i> , <b>2014</b> , 20, 399-400	1.1	7
113	Dermatomyositis autoantibodies: clinical markers of patients past, present, and future. <i>Archives of Dermatology</i> , <b>2011</b> , 147, 492-4		7
112	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , <b>2021</b> , 8,	4.6	7
111	Acute onset/flare of dermatomyositis following ingestion of IsaLean herbal supplement: Clinical and immunostimulatory findings. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 80, 801-804	4.5	6
110	Creation and Validation of Classification Criteria for Discoid Lupus Erythematosus. <i>JAMA Dermatology</i> , <b>2020</b> , 156, 901-906	5.1	6
109	The incidence of herpes zoster in cutaneous lupus erythematosus (CLE), dermatomyositis (DM), pemphigus vulgaris (PV), and bullous pemphigoid (BP). <i>Journal of the American Academy of Dermatology</i> , <b>2016</b> , 75, 42-8	4.5	6
108	Failure of physiologic doses of pure UVA or UVB to induce lesions in photosensitive cutaneous lupus erythematosus: implications for phototesting. <i>Photodermatology Photoimmunology and Photomedicine</i> , <b>2006</b> , 22, 290-6	2.4	6

107	Effect of TNF $\alpha$ blockade on UVB-induced inflammatory cell migration and collagen loss in mice. <i>Journal of Photochemistry and Photobiology B: Biology</i> , <b>2020</b> , 213, 112072	6.7	6
106	Environmental triggers of dermatomyositis: a narrative review. <i>Annals of Translational Medicine</i> , <b>2021</b> , 9, 434	3.2	6
105	Assessing the Correlation Between Disease Severity Indices and Quality of Life Measurement Tools in Pemphigus. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 2571	8.4	6
104	Bullous pemphigoid in adolescence. <i>Pediatric Dermatology</i> , <b>2019</b> , 36, 184-188	1.9	6
103	Fatigue in systemic lupus erythematosus and other autoimmune skin diseases. <i>British Journal of Dermatology</i> , <b>2019</b> , 180, 1468-1472	4	6
102	Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis. <i>British Journal of Dermatology</i> , <b>2020</b> , 182, 949-954	4	6
101	Utilization patterns and performance of commercial myositis autoantibody panels in routine clinical practice. <i>British Journal of Dermatology</i> , <b>2019</b> , 181, 1090-1092	4	5
100	Examining cutaneous disease activity as an outcome measure for clinical trials in dermatomyositis. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 80, 1793-1794	4.5	5
99	Classifying discoid lupus erythematosus: background, gaps, and difficulties. <i>International Journal of Women's Dermatology</i> , <b>2016</b> , 2, 8-12	2	5
98	Whither the patient-oriented researcher?. <i>Journal of the American Academy of Dermatology</i> , <b>1998</b> , 39, 109-113	4.5	5
97	The cutaneous lupus disease activity and severity index as a validated outcome measure for cutaneous lupus erythematosus: comment on the article by Stamm et al. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 59, 601-2		5
96	An Update on the Pathogenesis of Cutaneous Lupus Erythematosus and Its Role in Clinical Practice. <i>Current Rheumatology Reports</i> , <b>2020</b> , 22, 69	4.9	5
95	Safety, Tolerability, and Activity of ALXN1830 Targeting the Neonatal Fc Receptor in Chronic Pemphigus. <i>Journal of Investigative Dermatology</i> , <b>2021</b> , 141, 2858-2865.e4	4.3	5
94	Supplementing Dermatology Physician Resident Education in Vasculitis and Autoimmune Connective Tissue Disease: A Prospective Study of an Online Curriculum. <i>JAMA Dermatology</i> , <b>2019</b> , 155, 381-383	5.1	5
93	The proper future for medical dermatology. <i>Archives of Dermatology</i> , <b>1998</b> , 134, 1159-60, 1161-2		5
92	Pulmonary function tests, interstitial lung disease and lung function decline in outpatients with classic and clinically amyopathic dermatomyositis. <i>British Journal of Dermatology</i> , <b>2017</b> , 176, 262-264	4	4
91	Dermatological evaluation in patients with skin of colour: the effect of erythema on outcome measures in atopic dermatitis. <i>British Journal of Dermatology</i> , <b>2017</b> , 176, 853-854	4	4
90	Recent Advances in Pharmacological Treatments of Adult Dermatomyositis. <i>Current Rheumatology Reports</i> , <b>2019</b> , 21, 53	4.9	4

89	Evaluating cutaneous lupus disease activity end points and their effects on quality of life as an outcome measure for clinical trials. <i>British Journal of Dermatology</i> , <b>2019</b> , 181, 841-842	4	4
88	Cutaneous Lupus Erythematosus: Current Treatment Options. <i>Current Treatment Options in Rheumatology</i> , <b>2016</b> , 2, 36-48	1-3	4
87	Natural history of disease activity and damage in patients with cutaneous lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 79, 1053-1060.e3	4-5	4
86	Developing classification criteria for discoid lupus erythematosus: an update from the World Congress of Dermatology 2015 meeting. <i>International Journal of Women's Dermatology</i> , <b>2016</b> , 2, 44-45	2	4
85	The effects of immunostimulatory herbal supplements on autoimmune skin diseases. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 84, 1051-1058	4-5	4
84	Drug-induced dermatomyositis after lacosamide: A case report. <i>JAAD Case Reports</i> , <b>2018</b> , 4, 584-585	1-4	4
83	Highly Multiplexed Mass Cytometry Identifies the Immunophenotype in the Skin of Dermatomyositis. <i>Journal of Investigative Dermatology</i> , <b>2021</b> , 141, 2151-2160	4-3	4
82	SAT0255 A randomized, placebo-controlled, double-blind, ascending-dose, safety study of CC-220 in subjects with systemic lupus erythematosus <b>2017</b> ,		3
81	Disease severity and prophylactic measures in patients with cutaneous lupus erythematosus: results of a worldwide questionnaire-based study. <i>Postepy Dermatologii i Alergologii</i> , <b>2018</b> , 35, 192-198	1-5	3
80	Osteoporosis in health and disease: a dermatologist's perspective. <i>Dermatologic Clinics</i> , <b>2006</b> , 24, 241-9, vii	4-2	3
79	Measurement of disease severity in cutaneous autoimmune diseases. <i>F1000prime Reports</i> , <b>2013</b> , 5, 19		3
78	Ice-pack Dermatitis: A Diagnostic Pitfall for Dermatopathologists that Mimics Lupus Erythematosus. <i>Journal of Cutaneous Pathology</i> , <b>2016</b> , 43, 1-4	1-7	3
77	Plasma-derived DNA containing-extracellular vesicles induce STING-mediated proinflammatory responses in dermatomyositis. <i>Theranostics</i> , <b>2021</b> , 11, 7144-7158	12.1	3
76	Myeloid Dendritic Cells Are Major Producers of IFN- $\gamma$ in Dermatomyositis and May Contribute to Hydroxychloroquine Refractoriness. <i>Journal of Investigative Dermatology</i> , <b>2021</b> , 141, 1906-1914.e2	4-3	3
75	Launching lollipops? Perforating osteoma cutis in nephrogenic systemic fibrosis. <i>Journal of Cutaneous Pathology</i> , <b>2019</b> , 46, 467-470	1-7	2
74	Geospatial Correlation of Amyopathic Dermatomyositis With Fixed Sources of Airborne Pollution: A Retrospective Cohort Study. <i>Frontiers in Medicine</i> , <b>2019</b> , 6, 85	4-9	2
73	Evaluating the effect of prior authorizations in patients with complex dermatologic conditions. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 83, 1674-1680	4-5	2
72	The validity and utility of the Cutaneous Disease Area and Severity Index (CDASI) as a clinical outcome instrument in dermatomyositis: A comprehensive review. <i>Seminars in Arthritis and Rheumatism</i> , <b>2020</b> , 50, 458-462	5-3	2

71	Photosensitivity in Lupus Erythematosus and Dermatomyositis. <i>Current Dermatology Reports</i> , <b>2020</b> , 9, 93-99	1.5	2
70	1081 BIIB059, a monoclonal antibody targeting BDCA2, decreases Type I Interferon-related genes transcriptional activity in subjects with systemic lupus erythematosus (SLE) and active cutaneous LE (CLE). <i>Journal of Investigative Dermatology</i> , <b>2018</b> , 138, S183	4.3	2
69	1004 Increased tissue-resident memory T (TRM) cells and STAT3 expression in cutaneous lupus erythematosus patients refractory to antimalarials. <i>Journal of Investigative Dermatology</i> , <b>2019</b> , 139, S174	4.3	2
68	Skin Disease in Cutaneous Lupus Erythematosus <b>2013</b> , 319-332		2
67	Therapy of cutaneous lupus erythematosus. <i>Expert Review of Dermatology</i> , <b>2006</b> , 1, 105-120		2
66	Medical dermatology: a view to the future. <i>Journal of Investigative Dermatology</i> , <b>2006</b> , 126, 528-9	4.3	2
65	Pathogenesis of Cutaneous Lupus Erythematosus: The Role of Ultraviolet Light <b>2005</b> , 251-266		2
64	Glucocorticoids in autoimmune connective tissue diseases. <i>Dermatologic Therapy</i> , <b>2001</b> , 14, 134-142	2.2	2
63	Rho Kinase regulates neutrophil NET formation that is involved in UVB-induced skin inflammation.. <i>Theranostics</i> , <b>2022</b> , 12, 2133-2149	12.1	2
62	FRI0470 A phase 2 study of safety and efficacy of lenabasum (JBT-101), a cannabinoid receptor type 2 agonist, in refractory skin-predominant dermatomyositis <b>2018</b> ,		2
61	American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 2151-2160	9.5	2
60	Nuclear lamin B is crucial to the nuclear envelope integrity and extracellular trap release in neutrophils		2
59	Custom dental trays with topical corticosteroids for management of gingival lesions of mucous membrane pemphigoid. <i>International Journal of Dermatology</i> , <b>2020</b> , 59, e211-e213	1.7	2
58	Systemic sclerosis: Update for oral health care providers. <i>Special Care in Dentistry</i> , <b>2020</b> , 40, 418-430	1.7	2
57	Evaluating change in disease activity needed to reflect meaningful improvement in quality of life for clinical trials in cutaneous lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 84, 1562-1567	4.5	2
56	Accuracy of commercial panels to evaluate myositis autoantibodies: A single-institution perspective. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 84, 572-574	4.5	2
55	Increased MxA protein expression and dendritic cells in spongiotic dermatitis differentiates dermatomyositis from eczema in a single-center case-control study. <i>Journal of Cutaneous Pathology</i> , <b>2021</b> , 48, 364-373	1.7	2
54	605 Study of safety and efficacy of lenabasum, a cannabinoid receptor type 2 agonist, in refractory skin-predominant dermatomyositis. <i>Journal of Investigative Dermatology</i> , <b>2018</b> , 138, S103	4.3	2

53	SCLEROTIC SKIN DISEASE DEVELOPMENT FOLLOWING COVID-19 VACCINATION.. <i>JAAD Case Reports</i> , <b>2022</b> ,	1.4	2
52	Understanding cutaneous lupus erythematosus: a step forward. <i>British Journal of Dermatology</i> , <b>2019</b> , 180, 1292-1293	4	1
51	Candidate drug replacements for quinacrine in cutaneous lupus erythematosus. <i>Lupus Science and Medicine</i> , <b>2020</b> , 7,	4.6	1
50	Relative risk of microscopic colitis in dermatomyositis. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 81, 1188-1190	4.5	1
49	Bullous Pemphigoid, Mucous Membrane Pemphigoid and Pemphigus Vulgaris: An Update on Pathobiology. <i>Current Oral Health Reports</i> , <b>2014</b> , 1, 180-189	1.2	1
48	Effect of long-term treatment with tumour necrosis factor- $\alpha$ inhibitors on single-dose ultraviolet-induced changes in human skin. <i>British Journal of Dermatology</i> , <b>2017</b> , 177, 1762-1764	4	1
47	Importance of recognition and improved treatment for antimelanoma differentiation-associated protein 5-associated dermatomyositis. <i>British Journal of Dermatology</i> , <b>2017</b> , 177, 1168-1169	4	1
46	Cutaneous lupus erythematosus flare following exposure to surgical light during a dental procedure. <i>BMJ Case Reports</i> , <b>2015</b> , 2015,	0.9	1
45	Evaluating quality of life in dermatomyositis. <i>Expert Review of Dermatology</i> , <b>2010</b> , 5, 605-609		1
44	10 Annual Meeting of the Rheumatologic Dermatology Society. <i>Annals of Translational Medicine</i> , <b>2019</b> , 7, S159	3.2	1
43	The early local and systemic Type I interferon responses to ultraviolet B light exposure are cGAS dependent		1
42	Expert Perspective: An Evidence-Based Approach to Refractory Cutaneous Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 1777-1785	9.5	1
41	The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review. <i>Annals of Translational Medicine</i> , <b>2021</b> , 9, 431	3.2	1
40	Immunological and clinical heterogeneity in cutaneous lupus erythematosus. <i>British Journal of Dermatology</i> , <b>2021</b> , 185, 480-481	4	1
39	Drug-induced subacute cutaneous lupus erythematosus in previously diagnosed systemic lupus erythematosus patients: A case series. <i>JAAD Case Reports</i> , <b>2021</b> , 12, 18-21	1.4	1
38	The incidence of bullous pemphigoid continues to increase in England. <i>British Journal of Dermatology</i> , <b>2021</b> , 184, 5-6	4	1
37	Establishing cut-off values for mild, moderate and severe disease in patients with pemphigus using the Pemphigus Disease Area Index. <i>British Journal of Dermatology</i> , <b>2021</b> , 184, 975-977	4	1
36	Wong-Type Dermatomyositis in an African American Patient. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 630	9.5	1

35	Identifying the required degree of disease clearance to improve quality of life in pemphigus vulgaris. <i>British Journal of Dermatology</i> , <b>2021</b> , 184, 573-575	4	1
34	Response to: Correspondence on EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups by Irfan. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	1
33	The ALPHA Project: Establishing consensus and prioritisation of global community recommendations to address major challenges in lupus diagnosis, care, treatment and research. <i>Lupus Science and Medicine</i> , <b>2021</b> , 8,	4.6	1
32	Filgotinib or Lanraplenib in Moderate to Severe Cutaneous Lupus Erythematosus: A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study. <i>Rheumatology</i> , <b>2021</b> ,	3.9	1
31	Assessment and management of the heightened risk for atherosclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis.. <i>International Journal of Women's Dermatology</i> , <b>2021</b> , 7, 560-575	2	1
30	A Multidisciplinary Collaborative Approach to Retinal Toxic Effects Screening for Dermatology Patients Taking Antimalarials. <i>JAMA Dermatology</i> , <b>2021</b> , 157, 1112-1113	5.1	1
29	Dermatomyositis associated with hyponatremia and anasarca. <i>JAAD Case Reports</i> , <b>2021</b> , 16, 86-89	1.4	1
28	Erythromelalgia associated with dermatomyositis: A case series. <i>JAAD Case Reports</i> , <b>2021</b> , 16, 37-40	1.4	1
27	Cutaneous Diseases and the Esophagus 763-781		1
26	Dermatology vignette. Pseudoporphyria caused by NSAIDs. <i>Journal of Clinical Rheumatology</i> , <b>2001</b> , 7, 123	1.1	1
25	Evaluating results of an interferon- $\gamma$ release assay in patients with autoimmune disease who are taking hydroxychloroquine. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 80, 1162-1164	4.5	0
24	Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of Lenabasum.. <i>Arthritis Research and Therapy</i> , <b>2022</b> , 24, 12	5.7	0
23	Importance of collaboration of dermatology and rheumatology to advance the field for lupus and dermatomyositis.. <i>International Journal of Women's Dermatology</i> , <b>2021</b> , 7, 583-587	2	0
22	Clinical characteristics of itch in cutaneous lupus erythematosus: A prospective, multicenter, multinational, cross-sectional study. <i>Lupus</i> , <b>2021</b> , 30, 1385-1393	2.6	0
21	Increased CD69+CCR7+ circulating activated T cells and STAT3 expression in cutaneous lupus erythematosus patients recalcitrant to antimalarials.. <i>Lupus</i> , <b>2022</b> , 9612033221084093	2.6	0
20	Defining anti-synthetase syndrome: a systematic literature review.. <i>Clinical and Experimental Rheumatology</i> , <b>2022</b> , 40, 309-319	2.2	0
19	Challenges in measuring outcomes: size assessment of an individual cutaneous lesion. <i>Journal of the American Academy of Dermatology</i> , <b>2014</b> , 71, 402-4	4.5	
18	Update on Epidemiology and Clinical Assessment Tools of Cutaneous Lupus Erythematosus and Dermatomyositis. <i>Current Dermatology Reports</i> , <b>2013</b> , 2, 48-57	1.5	

17	OP0035 Progress Report on the Development of New Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, A60.2-A60	2.4
16	Cutaneous infections of the head and neck. <i>Facial Plastic Surgery Clinics of North America</i> , <b>2003</b> , 11, 165-73	
15	Ulcerating skin lesions and arthritis after a crab bite. <i>Journal of Clinical Rheumatology</i> , <b>2002</b> , 8, 181	1.1
14	Cutaneous Lupus <b>2022</b> , 25-52	
13	Cutaneous Outcome Measures of Adult Dermatomyositis <b>2019</b> , 1-7	
12	Management of autoimmune blistering diseases in pregnancy and the neonate. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , <b>2019</b> , 154, 539-549	0.8
11	Dapsone and Autoimmune Bullous Disorders <b>2015</b> , 493-499	
10	Pemphigoid Gestationis <b>2016</b> , 149-162	
9	THU0241 Ethnic but not gender differences in disease manifestations in dermatomyositis patients. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 71, 236.3-236	2.4
8	Response letter to Rhronic cutaneous lupus erythematosus induced by 5-fluorouracil? <i>Expert Review of Clinical Pharmacology</i> , <b>2020</b> , 13, 919-920	3.8
7	Individual patientsPrisk factors impact guidelines for prophylactic agents used in pemphigus patients treated with rituximab. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 85, e47-e48	4.5
6	Management of Cutaneous Lupus Erythematosus <b>2019</b> , 719-726	
5	Patient-oriented outcomes for atopic dermatitis. <i>British Journal of Dermatology</i> , <b>2021</b> , 184, 794-795	4
4	Response of dermatomyositis to the antimalarial quinacrine: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 84, 1157-1160	4.5
3	Letter to the Editor Reply Regarding ACR White Paper on Antimalarials and Cardiac Toxicity: Suggested Amendments to Future Directions.. <i>Arthritis and Rheumatology</i> , <b>2022</b> ,	9.5
2	Mycophenolate Mofetil and Methotrexate Efficacy in Dermatomyositis.. <i>British Journal of Dermatology</i> , <b>2022</b> ,	4
1	How do experts treat patients with bullous pemphigoid around the world? An international survey.. <i>JID Innovations</i> , <b>2022</b> , 100129	